Managing Patients on Oral Oncolytics

Conference Correspondent  - TOP - ASH 2015 - Multiple Myeloma, Conference Correspondent
Ali McBride, PharmD, MS, BCPS
Clinical Coordinator
The University of Arizona Cancer Center
Tucson, AZ

Ali McBride provides an overview of the role of the pharmacist and the importance of working with a broad team of healthcare providers in managing patients on oral oncolytics.

That's an excellent question. Right now, I work with a team of advanced practitioners, physicians, healthcare providers, and also finance to actually obtain a drug therapy for patients looking at dose adjustments, and also looking at compliance, or adherence for certain type of therapies.

We actually have a multi‑factorial role with multi‑disciplinary based evaluations for patients on oral oncolytics at this point. We have multiple roles, would be a better word for this. Making sure the patient is actually getting the drug which oftentimes for any first dose drug in the oral oncolytic, some patients may not even pick up that prescription, or even work on that prescription for several weeks later.

They're not even starting that therapy until a later time point. We have difficulties there as well. In addition, we also make sure the patient is getting the drug therapy. Sometimes, finance is a barrier.

Out of pocket expense has become an issue. We have seen a lot of work in regards to oral chemotherapy parity in which we're making sure the patients can actually afford those copays. Based on estate base legislation issues at each state across the country is also a federal act that's still in the pipeline right now.

We have numerous types of focuses. It may depend on the patient, it may depend on the physician, and what they want as well, but the goal is to make sure the patient has access to therapies, and they're adherent to therapies to make sure they maximize their outcomes with their treatment.

Related Items
Sexual Dysfunction After Cancer: Why Aren’t We Talking About It?
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in ONS 2018, Conference Correspondent
The Importance of Compassion: Perspective From a Lifelong Patient
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in ONS 2018, Conference Correspondent
Using a Team Approach to Tackle Opioid Abuse in Patients with Cancer
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in ONS 2018, Conference Correspondent
Addressing the Second Victim Phenomenon
Charles Bankhead
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in ONS 2018, Conference Correspondent
Palliative Care Use Dismal Among Patients with Hematologic Malignancies
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Palliative Care, Hematologic Cancers
Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss
Chase Doyle
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Multiple Myeloma
Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia
Wayne Kuznar
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Drug Updates, ASH
“Superhero” Navigators Convene at the 8th Annual Navigation & Survivorship Conference
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in AONN+ News, Conference Correspondent
Silent Patients Find Their Voices Through an Advocate’s Journey
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Patient Advocacy, Conference Correspondent, ESMO
Measuring Financial Well-Being in Cancer Survivorship
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Survivorship
Last modified: December 5, 2017